Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Breast Neoplasm Female × Ondansetron × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Vomiting 27 Nausea 22 Neoplasms 11 Lymphoma, Non-Hodgkin 6 Breast Neoplasms 6 Multiple Myeloma 5 Leukemia, Myeloid, Acute 5 Lymphoma, Large B-Cell, Diffuse 4 Burkitt Lymphoma 4 Uterine Cervical Neoplasms 3 Sezary Syndrome 3 Primary Myelofibrosis 3 Precursor Cell Lymphoblastic Leukemia-Lymphoma 3 Pancreatic Neoplasms 3 Neoplasm Metastasis 3 Myeloproliferative Disorders 3 Mycosis Fungoides 3 Lymphoma, T-Cell, Cutaneous 3 Lymphoma, Mantle-Cell 3 Lymphoma, Large-Cell, Immunoblastic 3 Lymphoma, Follicular 3 Lymphoma, B-Cell, Marginal Zone 3 Lymphoma 3 Leukemia, Myelomonocytic, Chronic 3 Leukemia, Myeloid, Chronic-Phase 3 Leukemia, Myeloid, Accelerated Phase 3 Leukemia, Lymphocytic, Chronic, B-Cell 3 Leukemia, Hairy Cell 3 Hodgkin Disease 3 Glioma 3

Interventions

Fulvestrant 2 venetoclax 1 pyrotinib 1 pertuzumab 1 palbociclib 1 dalpiciclib 1 anlotinib 1 Tretinoin 1 Trastuzumab 1 Ropivacaine 1 Radiosurgery 1 Propofol 1 Patient Reported Outcome Measures 1 Paclitaxel 1 Ondansetron 1 Morphine 1 Letrozole 1 Induction Chemotherapy 1 Etoricoxib 1 Docetaxel 1 Diagnostic Imaging 1 Carboplatin 1 Capecitabine 1 Anastrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03117894 2021-06-04

PECS-2 for Breast Surgery

Umeå University

Phase NA Completed

Breast Neoplasm Female

Data powered by HemOnc (CC BY 4.0) Colophon ⚡